Summary
LTF-SM, LTF-TZ, and LTF-RT represent three generations of incretin-receptor research compounds. Each engages a progressively larger set of receptors, which is the basis for substantial published comparative-pharmacology interest.
Overview
LTF-SM is a single-receptor (GLP-1) agonist. LTF-TZ is a dual-receptor agonist (GLP-1 and GIP). LTF-RT is a triple-receptor agonist (GLP-1, GIP, and glucagon). All three are synthetic peptides with structural modifications that extend half-life relative to the native incretin hormones.
Research Background
Interest in incretin agonists grew out of decades of work on glucose-stimulated insulin secretion and the physiology of the gut-pancreas axis. Each successive generation added receptor engagement based on observations from preclinical receptor pharmacology and energy-metabolism modeling.
Mechanisms Studied
Mechanistic studies have characterized the affinity and potency of each compound at its target receptors, the downstream second-messenger signals (cAMP, beta-arrestin), and the comparative selectivity profiles. Receptor-binding assays and cellular signaling readouts are the most-cited comparative endpoints.
Published Research Summary
Knudsen and Lau (2019) describe the discovery and pharmacology of LTF-SM. Coskun et al. (2018, 2022) describe the comparative receptor pharmacology of LTF-TZ (dual agonist) and LTF-RT (triple agonist) in preclinical models. Review articles increasingly position the three compounds as a coherent research lineage in incretin pharmacology.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.